Home Cart Sign in  
Chemical Structure| 94055-76-2 Chemical Structure| 94055-76-2

Structure of Suplatast (Tosilate)
CAS No.: 94055-76-2

Chemical Structure| 94055-76-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Suplatast Tosylate is an inhibitor of Th2 cytokine synthesis which can attenuate IL-2, IL-5 and IL-13 production and has no effect on IFN-γ production.

Synonyms: IPD 1151T; Suplatast tosilate; Suplatast (tosylate)

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Suplatast (Tosilate)

CAS No. :94055-76-2
Formula : C23H33NO7S2
M.W : 499.64
SMILES Code : C[S+](CCC(NC1=CC=C(OCC(O)COCC)C=C1)=O)C.O=S(C2=CC=C(C)C=C2)([O-])=O
Synonyms :
IPD 1151T; Suplatast tosilate; Suplatast (tosylate)
MDL No. :MFCD00867604
InChI Key :RYVJQEZJUFRANT-UHFFFAOYSA-N
Pubchem ID :71773

Safety of Suplatast (Tosilate)

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c mice DNP-KLH sensitized mice Oral 10, 30 or 100 mg/kg Once daily for 5 or 14 days To evaluate the inhibitory effect of IPD–1151T on bronchoconstriction and IgE production in DNP-KLH sensitized mice. Results showed that IPD–1151T inhibited both antigen- and MCh-mediated bronchoconstriction in a dose-dependent manner and significantly reduced total and specific IgE concentrations in serum. Mediators Inflamm. 2000;9(2):77-84
BALB/c and C57BL/6 mice EO771, 4T1 and EMT6 breast cancer models Intragastrical administration 100 mg/kg Starting at day four post tumor induction To evaluate the effect of IPD on breast cancer growth and immune microenvironment. Results showed IPD significantly inhibited tumor growth, promoted Th2 to Th1 switching, and remodeled the immune landscape. J Transl Med. 2022 Dec 23;20(1):615
Wistar rats Non-sensitized and sensitized rat model Oral 100 mg/kg Once daily for 6 days To investigate the effect of Suplatast on the half-life of IgE in the circulating blood, results showed that Suplatast facilitated the excretion of IgE from the circulation. Mediators Inflamm. 2002 Feb;11(1):61-4
BALB/c mice Allergic disorder model Intraperitoneal injection 100 mg/kg Once daily for 14 days To investigate the effects of IPD-1151T on the expression of co-stimulatory molecules CD40, CD80, and CD86. IPD-1151T significantly suppressed serum IgE levels and decreased IL-4 and IL-5 levels in splenic lymphocytes. Additionally, IPD-1151T suppressed CD40 and CD86 expression but did not affect CD80 expression. Mediators Inflamm. 2001 Dec;10(6):333-7
BALB/c mice Tuberculosis model Subcutaneous injection 16 nmol/g Once daily for 10 days Enhance the protective efficacy of BCG vaccine against tuberculosis J Biol Chem. 2014 Nov 28;289(48):33404-11

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.00mL

0.40mL

0.20mL

10.01mL

2.00mL

1.00mL

20.01mL

4.00mL

2.00mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories